# Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

> **NCT03370406** · PHASE1 · RECRUITING · sponsor: **Melissa Pugliano-Mauro** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** 5-fluorouracil
- **DRUG:** Calcipotriene

## Key facts

- **NCT ID:** NCT03370406
- **Lead sponsor:** Melissa Pugliano-Mauro
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-03
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370406, "Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03370406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*